Novo Nordisk Articles
Briefs: New research deals for AstraZeneca and Novo Nordisk; Lundbeck's Selincro launched in Europe
22 April 2013
New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients
18 March 2013
Novo Nordisk debuts Tresiba in UK and Denmark
4 March 2013
Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg
11 February 2013
New briefs on Pfizer interest in Protalix; Novo Nordisk warning letter; Hemispherx' Ampligen; and Idenix' hep C program
6 February 2013
Novo Nordisk 2012 net profit leaps 25% and sales rise 18%
31 January 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis
27 December 2012
News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus
20 December 2012
News briefs from Genmab/Kyowa Hakko; Alimera/Quintiles; Novo Nordisk; Astellas; Sandoz
5 December 2012
Positive new Ph III data on Novo Nordisk's Victoza
28 November 2012
Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"
23 November 2012
Global diabetes drugs market led by Novo Nordisk and Sanofi
14 November 2012
FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks
6 November 2012
Novo Nordisk net profit leaps 26% in first nine months of 2012
31 October 2012
Novo Nordisk files hemophilia drug turoctocog in USA and EU
17 October 2012
Japanese approvals for Eylea, Tresiba, Seebri and Aimix
1 October 2012
Novo Nordisk drops vatreptacog development
30 September 2012
Novo Nordisk invests $100 million for bigger R&D center in China
24 September 2012
Novo Nordisk ups forecast on strong diabetes drug sales
9 August 2012
FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg
19 July 2012
Highlights of American Diabetes Association meeting
11 June 2012
Exec appointments at Novo Nordisk and Teva
9 May 2012
New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit
2 May 2012
Novo Nordisk starts year with 15% net profits hike
30 April 2012
Novo Nordisk collaborates with Oxford University on RA and other inflammatory diseases research
25 April 2012
Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal
23 April 2012
Ground-breaking on new Novo Nordisk plant in Russia
17 April 2012
Pfizer and Biocon cancel biosimilars deal
14 March 2012
Victoza sales boost Novo Nordisk
3 February 2012
Novo Nordisk opens type 1 diabetes R&D center in Seattle
24 January 2012
Novo Nordisk reaches a milestone in stopping animal testing
29 November 2011
Denmark’s Novo Nordisk partners to tackle Qatar’s diabetes problem
24 November 2011
As US District Court dismisses patent use code counterclaim, all eyes move to the Supreme Court Prandin case, says law firm
22 November 2011
GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza
18 November 2011
EU OKs two new indications for Novo Nordisk’s Levemir
3 November 2011
Sanofi to top Pfizer as number one for global pharma sales
1 November 2011
AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza
10 October 2011
Novo Nordisk files for EU approval of ultra-long-acting insulins Degludec and DegludecPlus
28 September 2011
Obesity drug market set to grow to $2.6 billion by 2020, says DR report
27 September 2011
Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan
26 September 2011
Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS
13 September 2011
Senior appointments at Novo Nordisk and Sucampo
8 September 2011
Novo Nordisk extends free insulin and diabetes care program to India
7 September 2011
Novo Nordisk first-half 2011 sales and profit leap
4 August 2011
UCB agrees $34.4 million settlement for off-label promotion of Keppra in USA; Novo to pay $25 million over NovoSeven
13 June 2011
CytRx completes sale of molecular chaperone assets to Orphazyme ApS in deal worth up to $120 million
18 May 2011
China approves Novo Nordisk diabetes drug Victoza
16 March 2011
Novo Nordisk subpoenaed in the USA over marketing
16 February 2011
Diabetes pipeline cannot reverse cardiovascular and metabolic market decline, says Datamonitor
10 February 2011
Strong set of 2010 financials from Novo Nordisk
2 February 2011
Novo Nordisk to appeal adverse ruling in US Prandin patent case
20 January 2011
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
